- Cadence (CADX) was a compelling buy last year as the sales ramp for its IV acetaminophen formulation began to improve. A position since Mr. King first wrote on the name in December has returned more than 60%, but we believe it’s time to take profits.
- Early in the week, Mr. King took a retrospective look at trading Titan Pharmaceuticals’ (TTNP) FDA AdCom on the 23rd of March. For day-traders, there existed a defined path to trading the ins-and-outs of the advisory panel meeting, one that could easily come into play again in the future. Here’s an update on the company following the meeting.
- PropThink subscribers knew to short Novogen (NVGN) in late February after the stock popped well above fair value. That trade has pulled in 66% in less than a month.
- We’ve liked ENDP for a while given that analysts have slashed expectations to the bone. Now, the company’s new CEO, who we believe can turn the flagging business in a new direction, is on the road and updating investors on his strategy. We’re expecting a combination of acquisitions and divestitures to create value for shareholders. Since we called the trouble at ENDP an opportunity in December, shares have climbed 15%.
- BMRN is up 21% since we last wrote on the name. Ivan Deryugin outlined why he still likes the stock and believes there’s upside from here.
- Sarepta just keeps working higher. PropThink considers this a great long-term holding, and we outlined our strategy for being involved over the near-term. Shares are already up 18% in the last month.
- Synta (SNTA) has put together what Dr. Kotak sees as a clear path to success with its latest NSCLC clinical trial. Following a shelf registration, the recent slump has created a great entrance point ahead of ASCO.
- As expected, THLD proved a quality derivative play on ZIOP’s Phase III Palifosfamide data. The trade pulled in a quick 10% when the stock popped a few days after Mr. Patel’s story
